[{"id":"dcba04ab-be85-4463-b02a-c11e29e9a4ed","acronym":"WOKVAC","url":"https://clinicaltrials.gov/study/NCT02780401","created_at":"2021-01-18T13:38:17.343Z","updated_at":"2024-07-02T16:36:18.479Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission","source_id_and_acronym":"NCT02780401 - WOKVAC","lead_sponsor":"University of Washington","biomarkers":" HER-2 • IFNG • IL10 • IGFBP2","pipe":" | ","alterations":" HER-2 negative • HER-2 expression","tags":["HER-2 • IFNG • IL10 • IGFBP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/02/2016","start_date":" 09/02/2016","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2022-01-13"},{"id":"a5694c4f-4a89-466f-8e70-101ab026d285","acronym":"","url":"https://clinicaltrials.gov/study/NCT01322802","created_at":"2021-01-18T05:23:07.202Z","updated_at":"2024-07-02T16:36:34.081Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer","source_id_and_acronym":"NCT01322802","lead_sponsor":"University of Washington","biomarkers":" IFNG • IGFBP2","pipe":"","alterations":" ","tags":["IFNG • IGFBP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EP-201"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 03/06/2012","start_date":" 03/06/2012","primary_txt":" Primary completion: 01/09/2015","primary_completion_date":" 01/09/2015","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2021-02-25"},{"id":"f71419e3-ec56-43d9-8477-d9001d63eb30","acronym":"","url":"https://clinicaltrials.gov/study/NCT00503685","created_at":"2021-01-18T01:48:22.198Z","updated_at":"2024-07-02T16:37:10.264Z","phase":"Phase 2","brief_title":"Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy","source_id_and_acronym":"NCT00503685","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS • KIT • RAS • UGT1A1 • IGFBP2 • IGFBP3","pipe":" | ","alterations":" KRAS mutation • RAS mutation • RAS wild-type • UGT1A1*1*1","tags":["KRAS • KIT • RAS • UGT1A1 • IGFBP2 • IGFBP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation • RAS wild-type • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 06/01/2007","start_date":" 06/01/2007","primary_txt":" Primary completion: 03/01/2009","primary_completion_date":" 03/01/2009","study_txt":" Completion: 03/01/2009","study_completion_date":" 03/01/2009","last_update_posted":"2018-06-06"},{"id":"8ff4f0a2-31c3-4387-a5f5-4241f7a1484d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00821964","created_at":"2021-01-18T03:07:28.863Z","updated_at":"2024-07-02T16:37:15.145Z","phase":"Phase 2","brief_title":"Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT00821964","lead_sponsor":"University of Washington","biomarkers":" HER-2 • IFNG • TGFB1 • IGFBP2","pipe":"","alterations":" ","tags":["HER-2 • IFNG • TGFB1 • IGFBP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Zyclara (imiquimod)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 11/01/2012","primary_completion_date":" 11/01/2012","study_txt":" Completion: 11/29/2012","study_completion_date":" 11/29/2012","last_update_posted":"2018-01-02"},{"id":"b36841e1-96ea-4502-bf33-2aaee9562c1b","acronym":"WOKVAC","url":"https://clinicaltrials.gov/study/NCT03156309","created_at":"2021-01-18T15:33:44.760Z","updated_at":"2024-07-02T16:37:15.633Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission","source_id_and_acronym":"NCT03156309 - WOKVAC","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • IGFBP2","pipe":" | ","alterations":" HER-2 negative • HER-2 expression","tags":["HER-2 • IGFBP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukine (sargramostim)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":"","study_completion_date":"","last_update_posted":"2017-12-11"}]